Off-label use: The use of tocilizumab for indications not approved by the Food and Drug Administration will be discussed.
toxicities involving the gene-therapy vector have been reported in clinical trials of geneticallymodified T cells. [42] [43] [44] [45] Toxicities caused by CAR T cells damaging cells that express the targeted antigen CAR T cells could damage tissues that express the antigen recognized by the CAR. This mechanism of toxicity can be minimized but not eliminated by an exhaustive search for expression of a targeted antigen on normal tissues during preclinical development of a CAR. [46] [47] [48] Examples of this mechanism of toxicity have been reported in the literature. In one study, three patients with metastatic renal cell carcinoma who received infusions of autologous T cells transduced with a CAR targeting carboxy-anhydrase-IX (CAIX) experienced grade 3-4 increases in alanine aminotransferase, aspartate aminotransferase, or total bilirubin. 20, [49] [50] [51] Liver biopsies of affected patients revealed a cholangitis with a T-cell infiltration surrounding the bile ducts, and bile duct epithelial cells were unexpectedly found to express CAIX. 20, 49 A patient with metastatic colorectal cancer who received an infusion of autologous CAR T cells directed against the antigen ERBB2 (Her-2/neu) experienced acute respiratory distress and pulmonary edema requiring mechanical ventilation. She subsequently died. The pulmonary toxicity and subsequent death of the patient is hypothesized to be due to expression of ERBB2 on normal lung tissue. 32
Cross-reactivity of a CAR with a non-targeted protein
Organ damage could hypothetically occur when CAR T cells cross-react with an antigen expressed on normal tissue that is similar to the target antigen expressed by the malignancy. This toxicity has not been documented in clinical trials of CARs, but it has been observed in clinical trials of T cells genetically modified to express T-cell receptors (TCRs) . 33, 52, 53 For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
Allergic Reactions and tumor lysis syndrome
Allergic reactions to CAR T cells have been reported. A patient with pleural mesothelioma received multiple infusions of autologous T cells transduced with an anti-mesothelin CAR.
While he tolerated his first two cell infusions well, he experienced anaphylaxis and cardiac arrest one minute following completion of his third infusion, with dramatically elevated serum tryptase levels. He received cardiopulmonary resuscitation and recovered. 34 While chemotherapy may have caused TLS in some cases, the infusion of CAR T cells in the absence of prior conditioning chemotherapy has led to tumor lysis syndrome. 8, 13 CRS The most common acute toxicity of CAR T cells is CRS. The cytokines implicated in CRS may be directly produced by the infused CAR T cells, or other immune cells such as macrophages might produce cytokines in response to cytokines produced by the infused CAR T cells. A wide variety of cytokines including interleukin (IL)-6, interferon-γ (IFN-γ), tumor necrosis factor (TNF), IL-2, IL-2-receptor-α, IL-8, and IL-10 are elevated in the serum of patients experiencing fever, tachycardia, hypotension and other toxicities after CAR T-cell infusions. 4, [7] [8] [9] 11, 12, 35, 54 In one report, the severity of toxicity experienced by patients receiving anti-CD19 CAR T cells correlated with serum IFNγ and TNF levels. 16 Increased CRS grade was associated with increased sIL-2R levels, 5,11 peak IL-6 levels, 5, 6, 9, 11 peak ferritin, 5,9 peak CRP, 5,9 and higher levels of blood CAR T cells. 5, 6, 11 In some reports, the severity of CRS and elevation of serum cytokines have been related to disease burden, with higher disease burden predicting more toxicity. [4] [5] [6] [7] 9, 11 Predictive models of CRS based on cytokine profiles are in development. 7, 55 Figure 1 summarizes the organ toxicities caused by CRS.
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Derangements of coagulation following CAR T-cell infusion include prolongation of the prothrombin time (PT) and partial thromboplastin time and (PTT), 5,6,14 D-Dimer elevation, 8 low fibrinogen, 5,8 disseminated intravascular coagulation, 9 and macrophage activation syndrome. 5, 11 Hemorrhage is infrequent but possible. 5 Prolonged B-cell aplasia is an expected and common toxicity of anti-CD19 CAR T cells. 5, 6, [8] [9] [10] [11] [12] [13] [14] [15] [16] 31, 54 B-cell aplasia and hypogammaglobulinemia may last 2 months to over 2 years following CAR T-cell infusion. 4, 5, 16, 31 
Infectious Disease
Patients on CAR T-cell clinical trials frequently become neutropenic and lymphopenic following administration of chemotherapy followed by CAR T-cells. Such immune compromise predisposes these patients to opportunistic infection. In this setting, the fevers, tachycardia, and hypotension associated with CRS can be difficult to differentiate from sepsis. In an early report, a patient with CLL who received chemotherapy and anti-CD19 CAR T cells died with fever, hypotension, and renal failure. It was later found that this patient had elevated serum levels of inflammatory cytokines before CAR T-cell infusion, suggesting that the patient had a prior infection. 57 Bacteremia, 15, 16, 35 salmonella, 5 urinary tract infections, 15 and viral infections such as influenza, 16 respiratory syncytial virus, 13 and herpes zoster, 16 have also occurred following CAR T-cell infusion.
Musculoskeletal
Elevated creatine phospho-kinase (CPK) has been reported in a patient receiving anti-CD19 CAR T cells for ALL 6 and in two patients who received donor-derived allogeneic anti-CD19 CAR T cells. 6, 14 One of these patients also experienced myalgias and weakness. 14 
Similar muscle
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Neurologic Toxicities
Neurologic toxicities have been reported with other therapies in which serum cytokine levels are increased. Exogenous high-dose IL-2, when administered for solid tumor malignancies, can cause a global encephalopathy. 58 Blinatumomab, a bispecific antibody that both targets CD19 and activates T lymphocytes, can cause both a global encephalopathy as well as more localized defects such as aphasia, tremor, ataxia, hemiparesis, and cranial nerve palsies. 59, 60 The neurologic toxicities associated with anti-CD19 CAR T-cells are in many cases similar to the neurologic toxicities of blinatumumab can also be diverse, and do not localize to one specific area of neuroanatomy. The incidence of neurologic toxicity is quite variable, with published reports of 0-50%. [5] [6] [7] 9, 11, 14, 15 Neurologic events may occur at different times than CRS or in the absence of CRS toxicities, 5 which suggests that at least in some cases the neurologic toxicity might have a different mechanism than many of the other toxicities such as hypotension and fever. Reported neurologic toxicities include headaches, confusion, alterations in wakefulness, hallucinations, dysphasia, ataxia, apraxia, facial nerve palsy, tremor, dysmetria, and seizures. [4] [5] [6] [7] [8] [9] 11, 15, 16, 35 Neurologic toxicities may also necessitate intubation and mechanical ventilation for airway protection in absence of respiratory failure. 7 Central nervous system involvement of leukemia has not been shown to be associated with neurologic toxicity. 5,6 Multiple groups have found anti-CD19 CAR T cells in the cerebrospinal fluid (CSF) of patients, [5] [6] [7] [8] 15 and elevated IL-6 levels in the CSF have been observed in patients experiencing neurotoxicity. 35 In one series, higher levels of anti-CD19 CAR T cells were seen in the cerebral spinal fluid (CSF) of patients experiencing neurologic toxicities compared to patients without neurologic toxicities. 6 1 0
Graft Versus Host Disease (GVHD)
Allogeneic hematopoietic stem cell transplant recipients have received infusions of anti-CD19-CAR-transduced allogeneic T cells from their original transplant donors. In one report, donorderived virus-specific T cells transduced with an anti-CD19 CAR did not cause any GVHD in 8 post-transplant patients. 61 In another series of 20 patients receiving donor-derived allogeneic anti-CD19 CAR T cells, the only GVHD that occurred was slowly worsening chronic GVHD in a patient with pre-existing chronic GVHD and mild eye GVHD more than a year after CAR Tcell infusion in another patient. 13, 14 
Grading CRS
The Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE) includes a grading scale of CRS-related adverse events caused by immunotherapies, 62 but it was created for toxicity grading of acute infusional toxicities of monoclonal antibodies rather than T-cell therapies.
Another published rating scale for CRS integrates lab findings with clinical features. 7 A category of severe CRS (sCRS) is defined as CRS requiring pharmacologic and medical intervention. Criteria for sCRS are fevers of 38°C or greater for at least three consecutive days and elevation of two serum cytokines by 75-fold or of at least one serum cytokine by at least 250 fold, as well as one clinical sign of severe toxicity. 7 While this rating scale reliably identifies patients who will need intensive monitoring and intervention for CRS, obtaining real-time cytokine levels may not be possible at some facilities. Elevation of C-reactive protein (CRP) greater than 20 mg/dL correlates with severe CRS with a specificity of 100%, but the predictive value of this biomarker is unknown. 7 CRP may be helpful for identifying the peak point of toxicity and predicting toxicity resolution. 35 1 1 A widely referenced grading mechanism is a modification of the CTCAE to make it suitable for grading CRS due to T-cell therapies. 35 Grade 1 symptoms require only symptomatic management. Grade 2 symptoms respond to moderate intervention. These include oxygen requirement < 40%, grade 2 organ toxicity, or hypotension responding to IV fluids or low doses of one vasopressor, for example, < 20 μg/min of norepinephrine. Grade 3 CRS includes oxygen requirement greater than 40%, hypotension requiring high-dose or multiple vasopressors, grade 4 transaminitis, and grade 3 organ toxicity at other sites. Grade 4 CRS is defined as life-threatening symptoms requiring ventilator support or grade 4 organ toxicity other than transaminitis. 35
A third system of grading has been reported. 11 In this system, Grade 1 CRS requires only supportive care. Grade 2 CRS includes requirement for IV therapies, grade 2 creatinine elevation, grade 3 transaminitis, neutropenic fevers, and other indications for hospitalization. fraction, no history of myocardial infarction, and no cardiac arrhythmias, including atrial fibrillation. Good baseline bone marrow function with minimal cytopenias is important because of the possibility of cytopenias caused by either the conditioning chemotherapy or the CAR T cells. Patients who have undergone allogeneic stem cell transplant are not treated unless they have grade 1 or less acute GVHD or mild global score or less chronic GVHD.
For patients with significant disease burden, especially ALL with extensive marrow infiltration or NHL with bulky adenopathy, many groups start allopurinol for TLS prophylaxis prior to conditioning chemotherapy or prior to cell infusion 13,57
Following Cell Infusion: Hemodynamic Management and Supportive Care
Our practice for supportive care following cell infusion is summarized in Table 2 . Close hemodynamic monitoring is imperative following CAR T-cell therapy. At our center, patients remain hospitalized for at least 9 days after CAR T-cell infusion. At other centers, CAR T-cell infusions are performed on an outpatient basis. Vital signs are checked every 4 hours during the inpatient stay. If patients have heart rates persistently above 115 beats/minute, vital signs are checked every 2 hours. A complete blood count with differential and a comprehensive metabolic panel are drawn twice daily; uric acid and CRP are checked daily.
Fever is most often the first sign of CRS. Acetaminophen and cooling blankets can be used for fever management. We avoid corticosteroids for fever management because of the risk of inhibiting the CAR T cells. Non-steroidal anti-inflammatory medications are also not used for fever management because these agents could contribute to hemorrhage, gastritis, and renal insufficiency. If a patient is neutropenic and febrile, blood cultures should be drawn, and broad spectrum antibiotic therapy should be initiated. Infectious diagnoses should be aggressively 1 3 pursued by imaging and cultures to avoid missing infections in the setting of patients who are expected to be febrile secondary to CRS.
Hypotension must be recognized early and managed aggressively. At our center, systolic blood pressures (SBP) are used to guide hypotension management. The volume of fluid given for resuscitation varies greatly, and the approach must be tailored for each individual patient. For each patient, the benefit of volume resuscitation is weighed against the risk of vascular leak and pulmonary edema. Patients with hypotension that is not fluid responsive should receive vasopressors. We prefer norepinephrine as the first-line vasopressor.
The threshold for transfer to an intensive care unit will clearly vary among institutions.
Indications for transfer to the ICU at our center include SBP less than 75% of a patient's baseline and less than 100 mm Hg following a 1 Liter normal saline bolus, SBP less than 90 mm Hg following a 1 Liter normal saline bolus if 90 mm Hg is less than the patient's baseline systolic blood pressure, continuous tachycardia with heart rate higher than 125 beats per minute for at least 4 hours, oxygen requirement of more than 4 Liters flow by nasal cannula, and neurologic toxicity greater than grade 2 by the CTCAE version 4.0.
Cardiac arrhythmias and decrease in cardiac ejection fraction may occur during CRS and may be asymptomatic. Patients with other symptoms of CRS should be monitored with ECGs and echocardiograms. Our approach is to obtain an ECG, serum troponin, and echocardiogram for all patients who require more than one fluid bolus for hypotension, who are transferred to the ICU for hemodynamic management, or who require any dose of vasopressor for hypotension.
For patients maintained on vasopressors, repeated cardiac echocardiograms should be performed at least every 2 to 3 days.
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Cytopenias following cell infusion are managed with transfusion support and growth factors. Our practice is to initiate filgrastim when the ANC decreases to less than 500/mm 3 and to stop it when the ANC is greater than 1500/mm 3 . Transfusion support is provided to keep the hemoglobin at least 8.0 mg/dL and platelet count at least 20,000/mm 3 . Fresh frozen plasma is given for any grade 2 PTT prolongation, and cryoprecipitate is given when the fibrinogen is less than 100 mg/dL.
Tocilizumab
Tocilizumab is an IL-6 receptor antagonist that is used to treat rheumatologic disorders. 63,64 It has effectively treated CRS-related toxicities in clinical trials and is now widely used off-label for toxicity following CAR T-cell infusions. Tocilizumab can effectively lessen or abrogate the CRS-related toxicities following CAR T-cell infusions. [5] [6] [7] [8] 11 Resolution of CRS following administration of tocilizumab is demonstrated in Figure 2 .
Experience with treating ALL patients with tocilizumab demonstrated that complete remissions still occur when patients receive tocilizumab to treat CRS caused by CAR T cells. 5, 6 Some concern still exists that tocilizumab might subtly impair the depth or duration of antimalignancy responses caused by CAR T cells; formal studies of the impact of tocilizumab on anti-malignancy outcomes have not been performed. In addition, most published experience with tocilizumab is with ALL. Tocilizumab might impair the efficacy of CAR T cells against lymphoma or other malignancies even if it does not impair the activity of CAR T cells against ALL. The approach used in the set of guidelines published by Lee and colleagues is to administer tocilizumab to all patients experiencing CRS of grade 3 or greater and to patients with CRS of grade 2 or greater and comorbidities. 35 The goal of these guidelines is to avoid life-1 5 threatening grade 4 toxicity. Tocilizumab dosing varies among centers, and the agent may be given at a dose of 4 mg/kg or 8 mg/kg. There is general consensus that if CRS has not improved with initial tocilizumab administration, an additional dose of tocilizumab should be given or another immunosuppressive agent such as corticosteroids should be considered. 7, 35 Our practice is to give tocilizumab when specific hemodynamic and organ function thresholds are crossed, rather than for a certain grade of CRS. These criteria are listed in Table 3 .
We have used a dose of tocilizumab of 4 mg/kg infused over 1 hour, at a dose not to exceed 800 mg. If necessary, we administer a second dose of 4 mg/kg of tocilizumab. An initial dose of 8 mg/kg of tocilizumab might be optimal in some cases. We generally do not administer tocilizumab for neurologic toxicity because of concerns about the ability of tocilizumab to cross the blood brain barrier and experience in an admittedly very small number of patients that tocilizumab did not ameliorate neurologic toxicity. 35
Corticosteroids and other agents
Systemic corticosteroids have been used effectively to abrogate CRS related toxicities. 4, [6] [7] [8] 11, 54 Some evidence suggests that corticosteroids may inhibit CAR T-cell persistence and antimalignancy efficacy, as reported previously in ALL patients following anti-CD19 CAR T-cell infusion. 4,7 For this reason, corticosteroid therapy has been reserved for use following failure of tocilizumab to ameliorate CRS. Indications for giving corticosteroids differ among centers. At our center, corticosteroids are considered for CRS that does not improve following tocilizumab (Table 3 ). Other immunosuppressive agents that have been used or considered in CRS management include siltuximab, 65 etanercept, 8,9,35 infliximab, 35 and anakinra. 35 Due to paucity of data, no one second-line agent can be recommended over another.
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Management of Neurologic Toxicities
As neurologic toxicities may occur concurrently with or following resolution of CRS, it follows that management of these toxicities may differ from that of CRS alone. It is unclear if tocilizumab has any beneficial effect on neurologic toxicities. Because tocilizumab is a monoclonal antibody, its size makes efficient blood-brain barrier penetration unlikely. 66 The smaller molecule IL-6 is known to cross the blood-brain barrier and has been shown to cause neurologic defects. 67 Saturation of IL-6 receptors following systemic tocilizumab administration may increase serum IL-6 levels, 68 which could theoretically lead to an increase in cerebrospinal fluid IL-6 levels, which might worsen neurologic toxicity. Similar to other groups, 35 it is our practice to treat severe neurologic toxicities with systemic corticosteroids rather than tocilizumab as the first line agent. Dexamethasone is often chosen in this context because of its excellent central nervous system penetration (Table 3) . 69 We give dexamethasone for grade 3 neurologic toxicities other than headaches lasting more than 24 hours, grade 4 neurologic toxicities of any duration, and for any seizures. Our practice is for all patients with grade 2 or greater neurologic toxicity to be evaluated by the neurology consult service. For patients with seizures, standard anti-epileptic therapy is given. The management algorithm used for CRS and neurologic toxicity in adult patients at our center is delineated in Figure 3 .
Outpatient Monitoring
Hypogammaglobulinemia is common with the profound and prolonged B-cell aplasia that may occur following anti-CD19 CAR T cell infusions. Multiple groups have administered replacement therapy with intravenous immunoglobulins (IV IgG). 5, 11 Our practice is to administer IV IgG when the serum IgG level is less than 400 mg/dL. The utility of repeating 
Recombinant DNA Advisory Committee Symposium
On June 10, 2015, the NIH Recombinant DNA Advisory Committee (RAC) held a symposium, "Cytokine Release Syndrome after T-cell Immunotherapy," in Bethesda, Maryland. 70 Members of the RAC and researchers in the field of CAR T-cell therapy met to discuss the grading and management of toxicity. It was agreed that a single system for grading CRS toxicity would benefit the field as a whole.
The importance of vigilant monitoring and supportive care for patients experiencing CRS was discussed. Specifically, the importance of recognizing and treating concurrent infections early in the course was emphasized. The criteria used for tocilizumab infusion vary greatly among institutions, with some groups using a pre-emptive approach, giving tocilizumab during grade 1 toxicities, while other groups prefer to reserve the agent for high vasopressor requirement or impending need for mechanical ventilation. Small randomized trials of a preemptive versus reactive approach were posited as an avenue of further investigation. The use of corticosteroids to treat CRS was discussed. Some attendees stated that corticosteroids should be the first-line agent for severe neurologic toxicities, although a uniform threshold for their use has not been established.
Conclusion
Toxicities caused by CAR T cells are diverse and not fully understood. Management requires vigilant monitoring, aggressive supportive treatments, and, in some cases, intensive care.
8
Administering immunosuppressive agents to decrease toxicity is an evolving practice. Consensus guidelines for grading and managing toxicity will facilitate administration of CAR T cells at more centers. Improving the management of CAR T-cell toxicity is one of the most important avenues for overall improvement in the field of CAR T-cell therapies. : a  m  e  r  s  C  H  ,  S  l  e  i  j  f  e  r  S  ,  v  a  n  S  t  e  e  n  b  e  r  g  e  n  S  ,  e  t  a  l  .  T  r  e  a  t  m  e  n  t  o  f  m  e  t  a  s  t  a  t  i  c  r  e  n  a  l  c  e  l  l  c  a  r  c  i  n  o  m  a  w  i  t  h  C  A  I  X  C  A  R  -e  n  g  i  n  e  e  r  e  d  T  c  e  l  l  s  :  c  l  i  n  i  c  a  l  e  v  a  l  u  a  t  i  o  n  a  n  d  m  a  n  a  g  e  m  e  n  t  o  f  o  n  -t  a  r  g  e  t  t  o  x  i  c  i  t  y  .  M  o  l  T  h  e  r  .  2  0  1  3  ;  2  1  (  4  )  :  9  0  4  -9  1  2  .  2  1  .  A  h  m  e  d  N  ,  B  r  a  w  l  e  y  V  S  ,  H  e  g  d  e  M  ,  e  t  a  l  .  H  u  m  a  n  E  p  i  d  e  r  m  a  l  G  r  o  w  t  h  F  a  c  t  o  r  R  e  c  e  p  t  o  r  2  (  H  E  R D  u  t  c  h  e  r  J  ,  A  t  k  i  n  s  M  B  ,  M  a  r  g  o  l  i  n  K  ,  e  t  a  l  .  K  i  d  n  e  y  c  a  n  c  e  r  :  t  h  e  C  y  t  o  k  i  n  e  W  o  r  k  i  n  g  G  r  o  u  p  e  x  p  e  r  i  e  n  c  e  (  1  9  8  6  -2  0  0  1  )  :  p  a  r  t  I  I  .  M  a  n  a  g  e  m  e  n  t  o  f  I  L  -2  t  o  x  i  c  i  t  y  a  n  d  s  t  u  d  i  e  s  w  i  t  h  o  t  h  e  r  c  y  t  o  k  i  n  e  s  .  M  e  d  O  n  c  o  l  .  2  0  0  1  ;  1  8  (  3  )  :  2  0  9  -2  1  9  .  5  9  .  G  o  e  b  e  l  e  r  M  E  ,  K  n  o  p  S  ,  V  i  a  r  d  o  t  A  ,  e  t  a  l  .  B  i  s  p  e  c  i  f  i  c  T  -C  e  l  l  E  n  g  a  g  e  r  (  B  i  T • Administer acetaminophen for symptomatic management of fevers in patients with normal hepatic function.
• Provide cooling blankets for fevers > 40°C.
• Avoid corticosteroids and non-steroidal anti-inflammatory agents.
• Avoid meperidine. Cardiovascular
• Stop or taper antihypertensive medications prior to cell infusion.
• Monitor vital signs at least every 4 hours on an inpatient unit for at least 9 days following infusion.
• Monitor vital signs every 2 hours in patients with fevers and tachycardia.
• Initiate replacement intravenous fluids for patients with poor oral intake or high insensible losses to maintain net even fluid balance. • Administer intravenous fluid boluses for patients with systolic blood pressure less than their pre-infusion baseline.
o Patients with a systolic blood pressure less than 80% of their pre-infusion baseline and less than 100 mm Hg receive a 1 Liter normal saline bolus. o Patients with a systolic blood pressure less than 85 mm Hg receive a 1 Liter normal saline bolus regardless of baseline blood pressure. • Patients receiving more than 1 IV fluid bolus for hypotension or patients in the ICU for toxicity management have a serum troponin drawn and an electrocardiogram and an echocardiogram performed to evaluate for cardiac toxicity. • Patients with hypotension are initiated on vasopressor support. Norepinephrine is the preferred first-line vasopressor.
Infectious disease
• Initiate prophylactic antimicrobials, such as trimethoprim-sulfamethoxazole, for Pneumocystis prophylaxis prior to conditioning chemotherapy. • Initiate prophylactic antimicrobials, such as acyclovir or valacyclovir, for herpes virus prophylaxis prior to conditioning chemotherapy. • All patients with fevers and neutropenia have blood cultures drawn and broad-spectrum antibiotic coverage initiated. Hematologic
• Initiate allopurinol for tumor lysis syndrome prophylaxis in patients without a contraindication prior to conditioning chemotherapy. • Transfuse packed red cells for goal hemoglobin of ≥ 8.0 g/dL.
• Transfuse platelets for a goal platelet count of ≥ 20,000/μL. • Monitor complete blood count with differential twice daily. When absolute neutrophil count (ANC) decreases to < 500/μL, initiate filgrastim support. Continue until ANC increases to > 1,500 μL. • Transfuse fresh frozen plasma with a goal of normalization of partial thromboplastin time (PTT) in patients with a PTT 1.5-fold above the upper limit of normal or higher. • Transfuse cryoprecipitate to maintain fibrinogen of ≥ 100 mg/dL. If patient is bleeding, a higher level of fibrinogen should be maintained. • Left ventricular ejection fraction less than 40% by echocardiogram • Creatinine greater than 2.5-fold higher than the most recent level prior to CAR T-cell infusion • Norepinephrine requirement at a dose greater than 2 mg/minute for 48 hours since the first administration of norepinephrine, even if administration is not continuous • Systolic blood pressure of 90 mm Hg that cannot be maintained with norepinephrine • Oxygen requirement of fraction of inspired oxygen (FiO2) greater than 50% or more for more than 2 continuous hours • Dyspnea that is severe enough to potentially require mechanical ventilation • Activated partial thromboplastin time>2X upper limit of normal • Clinically-significant bleeding • Creatine kinase greater than 5x upper limit of normal for greater than 2 days Figure 1 : Cytokine release syndrome toxicities by organ system. After infusion of CAR T cells, CRS toxicities affecting a wide variety of organs can occur. 
Figure 2
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Neurologic toxicity meeting criteria for corticosteroids as listed in Table 3 ?
Yes No
Administer dexamethasone until significant improvement and continue supportive care per Table 2. CRS with indication for tocilizumab as listed in Table 3 ?
No
Continue supportive care as per Table 2 .
Yes
Administer tocilizumab and continue supportive care as per Table 2 .
Response within 12 hours?
Yes Continue supportive care per Table 2 Redose tocilizumab and consider second-line corticosteroids. Continue supportive care per Table 2 .
Patient experiences toxicity following CAR T-cell infusion.
No
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